All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb and Incyte. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mpn content recommended for you
What do we know about the outcome of concomitant MPN and COVID-19?
Featured:
Tiziano Barbui
Laura MichaelisDuring the First Annual Texas Virtual MPN Workshop, the MPN Hub spoke to our Steering Committee members Laura Michaelis, Medical College of Wisconsin, Milwaukee, US, and Tiziano Barbui, Papa Giovanni XXIII Hospital, Bergamo, IT. We asked, What do we know about the outcome of concomitant MPN and COVID-19?
What do we know about the outcome of concomitant MPN and COVID-19?
In this podcast, Tiziano Barbui starts by giving some background to the COVID-19 pandemic in Europe. Prof. Barbui has focused on how to help his patients with myeloproliferative neoplasms (MPN) during the outbreak. As a member of the European LeukemiaNet Working party on MPN, Prof. Barbui launched a study in 38 European centers, collecting 180 patients with both MPN and COVID-19. Laura Michaelis asks, are patients with MPN more susceptible to COVID-19 infection? Prof. Barbui discusses this question with reference the prevalence of people infected with COVID-19, who are asymptomatic but show serum-positivity.
Then, Prof. Michaelis asks what the fatality rate was in patients with MPN who also contracted COVID-19. Tiziano Barbui speaks about the results that he found in his hospital and in the study he commissioned. Laura Michaelis highlights that the stage of the epidemic also impacts on case fatality. They go on to comment on the type of comorbidities present in patients with MPN and how this effects their risk of severe disease with COVID-19. This leads to a discussion of the important variables identified during analysis of the data from Prof. Barbui's study. Prof. Michaelis in particular asks about how ruxolitinib modifies the risk for patients with MPN. Tiziano Barbui answers this, paying particular attention to the inflammatory environment in patients with COVID-19.